drugset / Trial / NCT04551950
Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)
Phase 1
Completed
25 enrolled
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study was to evaluate the safety and tolerability of bintrafusp alfa in combination with other anti-cancer therapies in participants with locally advanced or advanced cervical cancer.
Timeline
- Start
- 2020-10-19
- Primary completion
- 2022-06-15
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Bintrafusp alfa | Protein / enzyme biologic | — | — |
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Paclitaxel | Small molecule | — | Intravenous |
| Background | Cisplatin | Other / unclassified | — | Intravenous |